Valeant Backs Strategy With Solid Deal Record

27 Jul 2015

• By Lisa LaMotta

Reiterating the strength of its M&A-heavy strategy, Valeant CEO Michael Pearson touted the company's deal record during its second quarter earnings call.

Over the last five years Valeant Pharmaceuticals International Inc. has gone from a small Canadian dermatology company to a large multi-national conglomerate. This transformation was due to CEO Michael Pearson's vision of acquiring growth instead of focusing on in-house R&D.

Since Biovail Corp. bought Valeant in a reverse merger in June 2010, the new iteration of Valeant has been...